The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis

The paper discusses prospects for prescribing tumor necrosis factor-α (TNF-α) inhibitor biosimilars, their interchangeability with original drugs for inflammatory joint diseases. It describes clinical cases when original infliximab is replaced with its biosimilar Flammagis for ankylosing spondylitis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yu. V. Muravyev, V. V. Lebedeva, A. S. Starkova, D. G. Rumyantseva, M. M. Urumova, Sh. Erdes
Formato: Artigo
Idioma:Russo
Publicado em: IMA-PRESS LLC 2020-05-01
Colecção:Современная ревматология
Assuntos:
tumor necrosis factor-α inhibitors
biosimilars
rheumatoid arthritis
psoriatic arthritis
ankylosing spondylitis
flammagis
Acesso em linha:https://mrj.ima-press.net/mrj/article/view/1027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados